MedTrace Logo

An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine

NCT04713488 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2021-02-02

No results posted yet for this study

Summary

Phase I-II open prospective, two-stage, non-randomized study in healthy volunteers.

Conditions

  • COVID-19 Prevention

Interventions

BIOLOGICAL

Sputnik Light

solution for intramuscular injection Composition for 1 dose (0.5 ml)

Sponsors & Collaborators

  • Russian Direct Investment Fund

    collaborator INDUSTRY

  • Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
111 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2021-07-20
Completion
2021-07-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04713488 on ClinicalTrials.gov